Pill combo could replace harsh chemo for High-Risk leukemia

NCT ID NCT04817241

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of two oral medications (ASTX727 and venetoclax) can work as well as standard intravenous chemotherapy for younger adults (ages 18-65) with a high-risk form of acute myeloid leukemia (AML). The goal is to find a safe, effective dose and see if the all-oral approach improves outcomes like survival without the cancer returning. Only 5 participants were enrolled in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Locations

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467, United States
Montefiore Medical Center-Einstein Campus

The Bronx, New York, 10461, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.